DERIFENAC 7.5 Mg Tablet : Available on Steris Healthcare PVT LTD

DERIFENAC 7.5 Mg 

Darifenacin HBr ER (7.5mg)

DERIFENAC 7.5, containing Darifenacin HBr ER 7.5mg, is a medication primarily prescribed for the treatment of overactive bladder (OAB) symptoms. It belongs to a class of drugs known as antimuscarinics, which work by blocking specific receptors in the bladder, reducing bladder muscle contractions and alleviating symptoms such as urgency, frequency, and incontinence. This comprehensive guide aims to provide detailed information on its uses, dosage, price, side effects, composition, and more.

Uses:

1. Overactive Bladder (OAB): DERIFENAC 7.5 is indicated for the treatment of overactive bladder, a condition characterized by a sudden and frequent urge to urinate, often accompanied by urinary incontinence (urge incontinence) and increased urinary frequency.
2. Urinary Incontinence: It helps reduce episodes of urinary incontinence associated with OAB, improving patients' quality of life and bladder control.
3. Urgency: DERIFENAC 7.5 helps alleviate the sensation of urgency, allowing patients to better manage their bladder function and reduce the need for frequent bathroom visits.

Dosage:

The dosage of DERIFENAC 7.5 may vary depending on the patient's medical condition, age, and response to treatment. Typically, it is taken orally once daily, with or without food. The extended-release formulation allows for sustained release of the medication, providing symptom relief throughout the day. It's important not to crush, chew, or break the extended-release tablets, as this may affect the medication's efficacy and increase the risk of side effects.

Price:

The price of DERIFENAC 7.5 can vary depending on factors such as brand, dosage strength, and location. It's advisable to check with local pharmacies or online platforms for the most accurate pricing information. While the cost may vary, it is generally affordable, particularly when considering the improvement in quality of life it can provide for individuals with overactive bladder symptoms.

Composition:

DERIFENAC 7.5 contains Darifenacin hydrobromide extended-release (ER) as its active ingredient, with each tablet typically containing 7.5mg of Darifenacin. Darifenacin is a selective antagonist of muscarinic receptors, particularly the M3 subtype, located in the bladder. By blocking these receptors, Darifenacin inhibits bladder muscle contractions, thereby reducing the symptoms of overactive bladder.

Side Effects:

While DERIFENAC 7.5 is generally well-tolerated, it may cause side effects in some individuals. Common side effects may include:

1. Dry Mouth: Antimuscarinic effects may lead to reduced saliva production, resulting in dry mouth.
2. Constipation: Slowing of gastrointestinal motility can cause constipation in some patients.
3. Blurred Vision: Visual disturbances such as blurred vision or difficulty focusing may occur, particularly in individuals with pre-existing eye conditions.
4. Urinary Retention: In rare cases, DERIFENAC 7.5 may cause difficulty in emptying the bladder completely, leading to urinary retention.
5. Headache: Some individuals may experience mild to moderate headaches, although this is less common.

Precautions and Warnings:

Before taking DERIFENAC 7.5, patients should inform their healthcare provider about any pre-existing medical conditions, allergies, or medications they are currently taking. Certain precautions and warnings include:

1. Glaucoma: DERIFENAC 7.5 should be used with caution in individuals with narrow-angle glaucoma, as it may worsen the condition.
2. Urinary Retention: Patients with a history of urinary retention or bladder outlet obstruction should be closely monitored while taking DERIFENAC 7.5.
3. Gastrointestinal Disorders: Individuals with severe gastrointestinal conditions like severe constipation or ulcerative colitis may experience exacerbation of symptoms and should use DERIFENAC 7.5 with caution.
4. Pregnancy and Breastfeeding: The safety of DERIFENAC 7.5 during pregnancy and breastfeeding has not been established, and its use should be avoided unless the potential benefits outweigh the risks.

Conclusion:

DERIFENAC 7.5 is a valuable medication for the management of overactive bladder symptoms, providing relief from urgency, frequency, and urinary incontinence. By blocking muscarinic receptors in the bladder, it helps regulate bladder function and improve patients' quality of life. However, like any medication, it may cause side effects in some individuals, necessitating careful monitoring by healthcare professionals. With proper dosage and precautions, DERIFENAC 7.5 can effectively manage overactive bladder symptoms and enhance patients' overall well-being. Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

For further information: 

EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

CALL/WHATSAPP: 7877551268, 7849827488

BUY NOW